作为多种疾病治疗的DGAT2抑制剂的新型triazolopyridine衍生物
1Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
ACS medicinal chemistry letters
|September 18, 2024
概括
新型的三烯酸衍生物作为二甲醇O-转移酶2 (DGAT2) 抑制剂. 这些化合物为各种疾病提供了潜在的治疗应用,具有成熟的制备方法.
科学领域:
- 药用化学 医学化学
- 有机合成 有机合成
- 药理学 药理学是指药理学的学科.
背景情况:
- 甲糖醇O-转移酶2 (DGAT2) 是三甘油化合物合成中的一个关键酶.
- 调节失调的DGAT2活性与代谢障碍,如肥胖和糖尿病有关.
- 向DGAT2为管理脂质代谢提供了一种治疗策略.
研究的目的:
- 引入新型的三烯衍生物.
- 评估它们作为二甲糖醇O-转移酶2 (DGAT2) 抑制剂的潜力.
- 描述药物成分和制备过程.
主要方法:
- 合成新型的三烯酸衍生物.
- 在体外测试以评估DGAT2抑制活性.
- 制药成分的配方研究.
主要成果:
- 基于三二二基架的强效和选择性DGAT2抑制剂的发现.
- 在疾病模型中证明这些化合物的治疗效用.
- 为新型衍生品开发可扩展的合成路径.
结论:
- 新型的三烯衍生物是有效的DGAT2抑制剂.
- 这些化合物代表了治疗DGAT2相关疾病的有希望的候选药物.
- 描述的过程有助于制备这些治疗剂.
更多相关视频
06:07Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
2.5K
10:12A Fluorescence-based Assay for Characterization and Quantification of Lipid Droplet Formation in Human Intestinal Organoids
Published on: October 13, 2019
9.0K
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167
Parkinson's Disease: Treatment
235
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
235
Antidepressant Drugs: MAOIs and Other Agents
201
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
201
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
274
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
274
